Back to Browse Journals » OncoTargets and Therapy » Volume 6

Clinical appraisal of abiraterone in the treatment of metastatic prostatic cancer: patient considerations, novel opportunities, and future directions

Authors Bedoya DJ, Mitsiades N

Published Date January 2013 Volume 2013:6 Pages 9—18

DOI http://dx.doi.org/10.2147/OTT.S24941

Received 25 September 2012, Accepted 23 November 2012, Published 3 January 2013

Diego J Bedoya,1 Nicholas Mitsiades2,3

1
Clearview Cancer Institute, Huntsville, AL, USA; 2Department of Medicine, 3Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX, USA

Abstract: While androgen-deprivation therapy can induce dramatic clinical responses in advanced and metastatic prostate cancer, refractory disease (castration-resistant prostate cancer [CRPC]) eventually emerges. In recent years, several studies have demonstrated the importance of residual intratumoral androgens in maintaining androgen receptor (AR) transcriptional activity in CRPC. The cytochrome P450 enzyme CYP17 is an obligatory step in androgen synthesis, and therefore a critical therapeutic target in CRPC. Abiraterone acetate is a selective, irreversible inhibitor of CYP17 and can suppress adrenal synthesis of androgen precursors, and possibly in situ steroidogenesis in the tumor microenvironment. In a phase III multicenter study, abiraterone in combination with prednisone improved median overall survival of men with docetaxel-refractory CRPC by 3.9 months compared to placebo plus prednisone, and also resulted in higher objective prostate-specific antigen and radiographic response rates. The study led to the FDA approval in April 2011 of abiraterone for treatment of chemotherapy-refractory CRPC patients, validating steroidogenesis and the AR axis in general as therapeutic targets in CRPC. The FDA indication for abiraterone was expanded to all CRPCs in December 2012, while evaluation in even earlier disease states is ongoing. We propose a comprehensive AR axis-targeting approach via simultaneous, frontline enzymatic blockade of several steroidogenic enzymes (eg, CYP17 and AKR1C3) in combination with gonadotropin-releasing hormone analogs and potent, second-generation AR antagonists (eg, enzalutamide) in order to improve outcomes in patients with prostate cancer.

Keywords: androgen synthesis, testosterone, dihydrotestosterone, CYP17, AKR1C3, MDV3100 (enzalutamide)

Download Article [PDF] View Full Text [HTML] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Readers of this article also read:

Dose-effect relationship of CpG oligodeoxyribonucleotide 1826 in murine Lewis lung cancer treated with irradiation

Zhuang XB, Qiao TK, Yuan SJ, Chen W, Zha L, Yan L

OncoTargets and Therapy 2013, 6:549-554

Published Date: 20 May 2013

New dilemmas in small-cell lung cancer TNM clinical staging

Zarogoulidis K, Latsios D, Porpodis K, Zarogoulidis P, Darwiche K, Antoniou N, Hohenforst-Schmidt W, Eleftheriadou E, Boutsikou E, Kontakiotis T

OncoTargets and Therapy 2013, 6:539-547

Published Date: 16 May 2013

Pomalidomide: a novel drug to treat relapsed and refractory multiple myeloma

Terpos E, Kanellias N, Christoulas D, Kastritis E, Dimopoulos MA

OncoTargets and Therapy 2013, 6:531-538

Published Date: 10 May 2013

Treatment outcome of advanced pancreatic cancer patients who are ineligible for a clinical trial

Ueda A, Hosokawa A, Ogawa K, Yoshita H, Ando T, Kajiura S, Fujinami H, Kawai K, Nishikawa J, Tajiri K, Minemura M, Sugiyama T

OncoTargets and Therapy 2013, 6:491-496

Published Date: 8 May 2013

Effect and safety of bevacizumab-containing chemotherapy treatment in Chinese patients with metastatic colorectal cancer

Wu Q, Shi Y, Chen L, Xiao XY, Dai GH

OncoTargets and Therapy 2013, 6:485-490

Published Date: 30 April 2013

A review of the use of somatostatin analogs in oncology

Keskin O, Yalcin S

OncoTargets and Therapy 2013, 6:471-483

Published Date: 26 April 2013

Molecular guided therapy for advanced pancreatic cancer patients with PI3K activated mutation: vision or illusion?

Gazzah A, Gonzales DB, Levy A, Bahleda R, Ducreux M, Lacroix L, Soria JC

OncoTargets and Therapy 2013, 6:95-97

Published Date: 20 February 2013

Stereotactic body radiation therapy via helical tomotherapy to replace brachytherapy for brachytherapy-unsuitable cervical cancer patients – a preliminary result

Hsieh CH, Tien HJ, Hsiao SM, Wei MC, Wu WY, Sun HD, Wang LY, Hsieh YP, Chen YJ, Shueng PW

OncoTargets and Therapy 2013, 6:59-66

Published Date: 4 February 2013

Circadian rhythm characteristics of oral squamous cell carcinoma growth in an orthotopic xenograft model

Zhao NB, Tang H, Yang K, Chen D

OncoTargets and Therapy 2013, 6:41-46

Published Date: 23 January 2013

Learning curve for endoscopic thyroidectomy: a single teaching hospital study

Cao F, Jin K, Cui B, Xie B

OncoTargets and Therapy 2013, 6:47-52

Published Date: 23 January 2013